346 related articles for article (PubMed ID: 23801131)
21. Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.
Morita T; Ugai T; Tanimoto T; Matsue K
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24671324
[TBL] [Abstract][Full Text] [Related]
22. Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature.
Nayak HK; Kar P; Bagchi A; Kapoor N; Kapahtia S; Sonika U; Kumar N; Kumar S
JOP; 2013 Jan; 14(1):92-5. PubMed ID: 23306344
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Marchand T; Tas P; Houot R; Dauriac C; Lamy T; Cahu X
Eur J Haematol; 2011 Jul; 87(1):98. PubMed ID: 21418108
[No Abstract] [Full Text] [Related]
24. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Leblond V; Morel P; Dilhuidy MS; Leleu X; Soussain C; Leprête S; Dreyfus B; Dartigeas C; Mahé B; Anglaret B; Pégourié B; Besson C; Aurran T; Vekhoff A; Tournilhac O; Banos A; Oya H; Lejeune J; Ouzegdouh M; Chevret S;
Leuk Lymphoma; 2017 Nov; 58(11):2615-2623. PubMed ID: 28395585
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
26. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
27. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
Ghobrial IM; Vij R; Siegel D; Badros A; Kaufman J; Raje N; Jakubowiak A; Savona MR; Obreja M; Berdeja JG
Clin Cancer Res; 2019 Aug; 25(16):4907-4916. PubMed ID: 31142508
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
Ghobrial IM; Xie W; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Poon T; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
Am J Hematol; 2010 Sep; 85(9):670-4. PubMed ID: 20652865
[TBL] [Abstract][Full Text] [Related]
29. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
[TBL] [Abstract][Full Text] [Related]
30. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus cyclophosphamide and dexamethasone
Xiong W; Lyu R; Yu Y; Wang T; Yan Y; Wang Y; Liu W; An G; Deng S; Xu Y; Sui W; Huang W; Zou D; Wang J; Qiu L; Yi S
Haematologica; 2024 May; 109(5):1614-1618. PubMed ID: 38205507
[No Abstract] [Full Text] [Related]
32. [Waldenström macroglobulinemia].
Telek B; Batár P; Váróczy L; Gergely L; Rejtő L; Szász R; Miltényi Z; Simon Z; Udvardy M; Illés A
Orv Hetil; 2013 Dec; 154(50):1970-4. PubMed ID: 24317355
[TBL] [Abstract][Full Text] [Related]
33. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
34. Bilateral central retinal vein occlusion as an initial presentation of Waldenström macroglobulinemia: a case report.
Shrestha S; Poddar E; Bashyal B; Adhikari A; Pathak P; Acharya S; Sapkota S; Bhattarai A; Pant SR; Shrestha A
J Med Case Rep; 2023 Feb; 17(1):59. PubMed ID: 36804919
[TBL] [Abstract][Full Text] [Related]
35. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
36. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
[TBL] [Abstract][Full Text] [Related]
37. Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Guo HF; Su HL; Mao JJ; Sun C; Wang J; Zhou X
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):776-8. PubMed ID: 20979938
[TBL] [Abstract][Full Text] [Related]
38. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
Banwait R; O'Regan K; Campigotto F; Harris B; Yarar D; Bagshaw M; Leleu X; Leduc R; Ramaiya N; Weller E; Ghobrial IM
Am J Hematol; 2011 Jul; 86(7):567-72. PubMed ID: 21681781
[TBL] [Abstract][Full Text] [Related]
39. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone.
Aouba A; Pressiat C; Pricopi M; Georgin-Lavialle S; Boue F; Lievre-Castilla MA; Marfaing-Koka A; Prevot S; Decottignies A
Dermatology; 2015; 230(1):18-22. PubMed ID: 25471063
[TBL] [Abstract][Full Text] [Related]
40. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
